For more on preparing for GLP-1 treatment, see what to know before starting semaglutide
METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI 35 kg/m 2
Vai M, Brambilla L, Orlandi I, Rota N, Ranzi BM, Alberghina L, Porro D (2000) Improved secretion of native human insulin-like growth factor 1 from gas1 mutant Saccharomyces cerevisiae cells
It can boost energy levels and lead to a supporting proper metabolism of proteins, fats, and carbohydrates